Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. - Wikidata - awgldk - TriplyDB

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

http://www.wikidata.org/entity/Q30330620

about

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions Antiviral activity of CYC202 in HIV-1-infected cells Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.DNA/MVA Vaccines for HIV/AIDS Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers Non-human primate models for AIDS vaccine research.Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients.DNA vaccines against human immunodeficiency virus type 1 in the past decade.SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity.Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Therapeutic vaccines against HIV infection.Developments in virus-like particle-based vaccines for HIV.Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

P2860

Q21135240-89064CF3-1229-481D-9A4A-5BE2492DBBFF Q27320923-2D33CEF2-9C41-4A6B-AC04-DA440AFBF9C6 Q28292152-F8B13F00-47BA-42AE-8BAC-66B4D0DD9C61 Q30339052-681A0E7B-FFDB-4DF4-AF05-EEFE2CACC1CA Q30366666-A141D237-7A65-4E34-BF75-41B83EBB6C52 Q30381447-A5449811-9699-4470-978C-09C1FD43864A Q33627613-4E15EC63-E4AA-456E-B1C9-6D44EB68A246 Q33737723-58AB24AA-42A5-4A10-B8C3-201F379A6624 Q33755041-112308E8-3C8C-4C3D-8BA5-0B12A6CC9E80 Q33826983-C6D72A9A-434D-4B9F-A84F-833F09BE2C86 Q34059531-131725FF-F622-4A97-92F0-B07C60727D17 Q34226966-9BF89246-66BC-4C8B-988B-71FB44A70ACD Q34227778-B4C8D575-0929-401D-839C-F0605CDAD99A Q34348561-3117C2ED-BEF6-4A06-BF08-5739A38660CD Q34492802-BD747EFF-119A-4AAD-97A4-5991560184CC Q34589611-1ABF2ACD-7A2D-4120-A8BE-74DEB1F5245B Q34715769-5B0C908E-C78E-484D-8995-3BCA56053FEC Q34772727-561C808B-45BF-40DE-BEB5-61CE20BE6B16 Q35183962-3F00F31B-9ABD-43A5-B01E-6626692591C5 Q35745831-0B126BF8-9793-4A78-90E8-5B38A941EE39 Q35754196-F553516B-1D91-43D2-86B6-5EB58649FD0A Q36129034-7B5F72C5-3B07-4EC6-9B7D-4641C6101529 Q36141586-8E7ABFDA-4269-4DB1-9282-85CB02B81602 Q36141610-A6CA6F68-AD87-4A58-A7C9-30999ECA6381 Q36424574-B7BF5864-5302-4910-B6FB-D029084FC871 Q36473859-C2F6CF4D-EDDB-4DC6-8978-A8E9C5756EE4 Q36532471-055325D9-B09F-4443-AD21-53C590080DF1 Q36538907-7ED67B1B-C282-4D18-8222-89F3D6C97EE9 Q36728808-53EA1987-D8FD-4F11-9B81-713B2AEB2576 Q37346420-BB8EEE98-1496-49A1-BD67-7BC0D2883EB0 Q37355979-5ACE800A-B12C-477D-AD17-1DA8FA9DEFE1 Q37656908-CC43FDBE-2BCA-491B-A611-28F10714F4A5 Q37682968-119A6DEF-E675-427C-82A5-FF940F245317 Q37743813-C7314734-2DC2-43D5-83C4-7F48002C45BF Q37785949-B15274FF-8FB6-443C-8A7B-08F9FDD2EFEC Q38013505-109DB2EA-7E20-4BB9-BC86-42255E2B8184 Q38081965-A102BCA4-8BA1-4265-9BFE-1D92E2FD6E0D Q38541824-82AEF65A-378C-43EE-9189-8740FE8F6B60 Q39756926-6C71D746-211C-420B-B080-B514686A71A1 Q40071705-26D58428-4717-46DF-8CFE-028CF408829C

P2860

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

http://www.wikidata.org/entity/Q30330620

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@ast

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@en

type

label

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@ast

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@en

prefLabel

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@ast

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@en

P1433

Q30330620-31CFB784-CCA0-49A1-A74E-3C023359A305

P1476

Q30330620-BC6F1A71-8354-4929-91A2-7815AE963DA1

P2093

Q30330620-3025B0F2-2817-40D2-92FD-4B5805632B57

Q30330620-38B9CB04-C69D-4404-8335-690386FA0FCF

Q30330620-55C1CBCD-B559-41A3-B5A3-B4159AEEC055

Q30330620-6941D693-6E42-4CBF-93DE-BE58267E2D8A

Q30330620-6967BAF8-DAB3-431C-BEC9-AA98045A72BB

Q30330620-87EC316A-C48B-4581-A202-6FADF5516400

Q30330620-B5899974-73CD-48CC-8DD7-E66F6CAC1451

Q30330620-BCBD0FFA-9647-48B0-984A-AB7570FF799F

Q30330620-D83049C7-20DC-4935-868D-C364F2D1DD9C

Q30330620-DE5B27A3-BC90-4FF4-BB6D-2EBF8BA4273E

P2860

Q30330620-0BC6B706-6753-4EC6-8900-89D1DE03648C

Q30330620-34AD228C-E692-4A75-8180-D102BA2C391E

Q30330620-445188FD-21C5-4A8C-8EA3-9E53DC46A115

Q30330620-47AC1B6A-C558-463E-992F-749ABCA3C200

Q30330620-5DD0FE10-0E12-4C5A-99C8-E423FB167485

Q30330620-6709E5F2-8EE0-4582-B18E-3A28BB9696DE

Q30330620-7075D3C6-D94B-4175-8861-B4A1E36A1E47

Q30330620-71C17899-F22A-4F67-96B8-C78E67891539

Q30330620-8EBBEABD-1EB9-4763-ACEF-41B209D28106

Q30330620-9A3EA7C1-4300-4519-9AE2-368F98D6FA45

P304

Q30330620-B3699769-835C-4475-9FB9-A5EFF724DE60

P31

Q30330620-BB0F905E-34CB-4487-815E-F2B9DD14D708

P356

Q30330620-FC26B276-2E9B-4FA2-A0BF-91F2F17122DB

P433

Q30330620-F6082123-A102-4241-BFBC-1D97BD9012CF

P478

Q30330620-4B4D6112-73B7-48B9-A08A-446E39031FEF

P50

Q30330620-07F8DC48-3CFA-4E3E-8284-3A18421F28AB

Q30330620-F6D6EDF7-781B-4A17-A706-5F5D8803F70C

P577

Q30330620-C71D3442-F035-4447-85E6-E454F120CD44

P5875

Q30330620-6838B85D-7DA4-4F35-90BF-A64737A33C35

P698

Q30330620-6637A5E7-7554-4CFC-8069-FFA1528C344A

P932

Q30330620-B6EA17D6-0E35-4E80-AEE5-0A72B5687DCE

P356

JVI.76.15.7625-7631.2002

P1433

Journal of Virology

P1476

Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.

@en

P2093

Francois Villinger

http://www.w3.org/2001/XMLSchema#string

Harold M McClure

http://www.w3.org/2001/XMLSchema#string

Harriet L Robinson

http://www.w3.org/2001/XMLSchema#string

James G Herndon

http://www.w3.org/2001/XMLSchema#string

John D Altman

http://www.w3.org/2001/XMLSchema#string

Linda S Wyatt

http://www.w3.org/2001/XMLSchema#string

Natalia L Kozyr

http://www.w3.org/2001/XMLSchema#string

Patricia L Earl

http://www.w3.org/2001/XMLSchema#string

Rama Rao Amara

http://www.w3.org/2001/XMLSchema#string

Silvija I Staprans

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele

Nonreplicating vaccinia vector efficiently expresses recombinant genes.

P304

7625-7631

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.15.7625-7631.2002

http://www.w3.org/2001/XMLSchema#string

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11277682

http://www.w3.org/2001/XMLSchema#string

P698

12097576

http://www.w3.org/2001/XMLSchema#string

P932

136377

http://www.w3.org/2001/XMLSchema#string